Session Tracks

This track will explore the latest research on molecular markers associated with metabolic syndrome and Type 2 diabetes. Emphasis will be placed on the identification and validation of inflammatory markers that can aid in early diagnosis and treatment strategies.

This session will focus on advancements in pharmacotherapy for diabetes, highlighting new drug treatments and their mechanisms of action. Discussions will include the efficacy and safety profiles of emerging therapies in clinical practice.

This track will cover the development and implementation of novel devices for diabetes management, including insulin pumps and artificial beta cells. Participants will discuss the impact of these technologies on patient outcomes and quality of life.

This session will delve into the advancements in closed-loop systems for diabetes management, including the Biostator technology. The focus will be on how these systems can improve glycemic control and reduce the burden of diabetes management.

This track will examine the latest innovations in insulin delivery methods, including the development of insulin pens and other novel techniques. The aim is to enhance patient adherence and optimize glycemic control.

This session will address the unique challenges and management strategies for diabetes in pediatric populations and during gestation. Discussions will include the implications of hyperglycemia and diabetes on maternal and child health.

This track will focus on the complexities of autoimmune diabetes mellitus and monogenic forms of diabetes, including neonatal diabetes. Participants will explore genetic underpinnings and potential therapeutic approaches.

This session will investigate the role of immune interventions in the prevention and management of prediabetes. The discussion will include emerging therapies aimed at modulating immune responses to delay or prevent diabetes onset.

This track will focus on clinical strategies for managing diabetes and its associated complications. Emphasis will be placed on diagnostic approaches and patient-oriented case management.

This session will highlight recent advancements in the discovery of biomarkers for diabetes treatment. The focus will be on how these biomarkers can inform therapeutic decisions and improve patient outcomes.

This track will explore the regulatory and economic considerations in diabetes research and treatment. Discussions will include the implications of policy changes on research funding and access to innovative therapies.